Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Zanelli, Magda; Loscocco, Giuseppe G.; Sabattini, Elena; Zizzo, Maurizio; Sanguedolce, Francesca; Panico, Luigi; Fanni, Daniela; Santi, Raffaella; Caprera, Cecilia; Rossi, Cristiana; Soriano, Alessandra; Cavazza, Alberto; Giunta, Alessandro; Mecucci, Cristina; Vannucchi, Alessandro M.; Pileri, Stefano A.; Ascani, Stefano
    • Publication Date:
      2021
    • Collection:
      Università degli Studi di Cagliari: UNICA IRIS
    • Abstract:
      Simple Summary Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia. Given important therapeutic implications, it is crucial to identify T-LBL arising in this particular context. LIM domain only 2 (LMO2) is known to be overexpressed in almost all sporadic T-LBL and not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations. We retrospectively evaluated the clinical, morphological, immunohistochemical and molecular features of 11 cases of T-LBL occurring in the setting of myeloid/lymphoid neoplasms with eosinophilia and investigated the immunohistochemical expression of LMO2 in this setting of T-LBL. Interestingly, 9/11 cases were LMO2 negative, with only 2 cases showing partial expression. In our study, we would suggest that LMO2 immunostaining, as part of the diagnostic panel for T-LBL, may represent a useful marker to identify T-LBL developing in the context of myeloid/lymphoid neoplasms with eosinophilia. Background: Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo), a group of diseases with gene fusion resulting in overexpression of an aberrant tyrosine kinase or cytokine receptor. The correct identification of this category has relevant therapeutic implications. LIM domain only 2 (LMO2) is overexpressed in most T-LBL, but not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations (iT-LBP). Methods and Results: We retrospectively evaluated 11 cases of T-LBL occurring in the context of M/LNs-Eo. Clinical, histological, immunohistochemical and molecular features were collected and LMO2 immunohistochemical staining was performed. The critical re-evaluation of these cases confirmed the diagnosis of T-LBL with morphological, immunohistochemical and molecular features consistent with T-LBL occurring in M/LNs-Eo. Interestingly, LMO2 immunohistochemical analysis was negative in 9/11 cases, whereas only ...
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/34205834; info:eu-repo/semantics/altIdentifier/wos/WOS:000666257500001; volume:13; issue:12; numberofpages:17; journal:CANCERS; http://hdl.handle.net/11584/315037; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85108175133
    • Accession Number:
      10.3390/cancers13123102
    • Online Access:
      http://hdl.handle.net/11584/315037
      https://doi.org/10.3390/cancers13123102
    • Rights:
      info:eu-repo/semantics/openAccess
    • Accession Number:
      edsbas.F5A892EA